TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28358815
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with steroids and azathioprine
Study: 25981347
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (CF) at doses of 5.3 mg and 10.7 mg total CF/kg body weight (BW)
Study: 25981347
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g) as control
Study: 21415263
Drug: Supervised treadmill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised treadmill training for 12 weeks at home, exercising twice a week at an intensity of 66% of HR(peak)
Study: 18021477
Drug: Taxanes in
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes in both treatment arms
Study: 3016080
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human fibroblast interferon
Study: 31516094
Drug: Probiotics +
Normalized name: Culturelle Probiotics + Multivitamin Gummies (Mixed Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics + sertraline (PS)
Study: 31516094
Drug: Sertraline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline alone (S)
Study: 31806719
Drug: Individualised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised treatment targeting treatable traits
Study: 28763875
Drug: Nattokinase (NK)
Normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattokinase (NK) at a daily dose of 6000 FU for 26 weeks
Study: 28763875
Drug: Statin (simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (simvastatin 20 mg) daily for 26 weeks
Study: 26268133
Drug: 2h abbreviated
Normalized name: (2H)-Phthalazinone hydrazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2h abbreviated fasting with oral ingestion of a carbohydrate and protein solution
Study: 21732797
Drug: Insulin bolus-patch
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin bolus-patch
Study: 10868638
Drug: Quadruple induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple induction therapy (tacrolimus, azathioprine, ALG Merieux, and prednisolone)
Study: 10868638
Drug: Dual induction
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual induction therapy (tacrolimus and prednisolone)
Study: 10868638
Drug: Quadruple induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple induction therapy
Study: 10868638
Drug: Dual induction
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual induction therapy
Study: 8218538
Drug: rhIL-3 (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-3 (highest dose levels)
Study: 3957502
Drug: Flunarizine 20
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 20 mg/per os/day for 14 days, followed by 10 mg/per os/day up to 120 days
Study: 2454374
Drug: Carvedilol i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol i.v. (15 mg)
Study: 2454374
Drug: Labetalol i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol i.v. (40 mg and 80 mg)
Study: 31554874
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (group A with 13 cases)
Study: 31554874
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (group A)
Study: 25738668
Drug: Goserelin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin with standard chemotherapy
Study: 23385648
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg, titrated to 10 mg)
Study: 23385648
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg, titrated to 100 mg)
Study: 26618715
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg GOE
Study: 26618715
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg GOE
Study: 19752363
Drug: 5g IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g IV MgSO(4) followed by daily 4-hour infusions from postoperative day 1 until postoperative day 4
Study: 7874899
Drug: 0.50 mL
Normalized name: witch hazel 0.50 mL in 1 mL TOPICAL SOLUTION [Medicated Pads]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mL normal saline injection
Study: 7874899
Drug: 0.75 mL
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mL normal saline injection
Study: 7874899
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL normal saline injection
Study: 7874899
Drug: 0.25 mL
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mL normal saline injection
Study: 7874899
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injections (all volumes)
Study: 763213
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 250 mg of lidocaine in a 10% solution into the deltoid muscle
Study: 763213
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 250 mg of lidocaine in a 10% solution into the lateral vastus muscle
Study: 31503180
Drug: PIP in
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIP in combination with major depressive disorder (MDD)
Study: 29050954
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with a target dose of 48-54 Gy in six fractions
Study: 25562685
Drug: Paliperidone monthly
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paliperidone monthly
Study: 22431145
Drug: VPT/CEM (Vital
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPT/CEM (Vital Pulp Therapy with Calcium-Enriched Mixture Cement)
Study: 19530584
Drug: Epidural nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural nalbuphine 5 mg
Study: 19530584
Drug: Epidural nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural nalbuphine 10 mg
Study: 11559309
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine hydrochloride (2-10 mg, n = 20)
Study: 11559309
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine hydrochloride (2-10 mg)
Study: 9733667
Drug: Oral ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ifosfamide with methylene blue (50 mg po 3 times daily)
Study: 9733667
Drug: Intravenous ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ifosfamide (one of the first two cycles)
Study: 9733667
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue administration
Study: 3184889
Drug: Cocaine 15
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 15 mg
Study: 3184889
Drug: Cocaine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (15 mg and 40 mg combined)
Study: 25163819
Drug: 17OHPC (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17OHPC (250 mg weekly injections)
Study: 16518962
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (zidovudine/lamivudine/efavirenz)
Study: 16518962
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (abacavir/lamivudine/zidovudine/tenofovir)
Study: 14734394
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (1mEq/l) administration
Study: 14734394
Drug: Historical factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical factors (chief complaint, medical history, specific disease conditions, overall drug use)
Study: 7924776
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (720 pM.m-2.min-1) during hypoglycemia (target plasma glucose, 2.8 mM)
Study: 7924776
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin infusion rate (1,440 pM.m-2.min-1)
Study: 2729537
Drug: Intratracheal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal administration of 10 ml 0.9% NaCl (group 4)
Study: 30938035
Drug: FBG target
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBG target of 3.9 < FBG ≤5.6 mmol/L (Group 1)
Study: 30938035
Drug: FBG target
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBG target of 3.9 < FBG ≤6.1 mmol/L (Group 2)
Study: 30938035
Drug: FBG target
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBG target of 3.9 < FBG ≤7.0 mmol/L (Group 3)
Study: 23126492
Drug: Apical box
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical box preparation (size #60)
Study: 23126492
Drug: Apical cone
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical cone preparation (apical size #25)
Study: 19561263
Drug: Immunoembolization (IE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoembolization (IE) with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) at high-dose (>or=1500 microg)
Study: 8779400
Drug: Randomized studies
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized studies in emergency medicine
Study: 2008953
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IT morphine and epidural bupivacaine
Study: 7035953
Drug: Cyclophosphamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (2 mg per kilogram of body weight per day) with prednisone in tapering doses
Study: 7035953
Drug: Chlorambucil (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.15 mg per kilogram per day) with prednisone in tapering doses
Study: 7035953
Drug: Cytotoxic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic drugs (Cyclophosphamide or Chlorambucil)
Study: 11524351
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 2% lidocaine
Study: 26099868
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 25-mg tramadol
Study: 26099868
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 2% lidocaine + 25-mg tramadol
Study: 21956725
Drug: Clobazam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 1.0 mg/kg/day
Study: 15330492
Drug: Hibiscus sabdariffa
Normalized name: HIBISCUS SABDARIFFA CALYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabdariffa extract (10 g dry calyx in 0.51 L water, 9.6 mg anthocyanins)
Study: 1461544
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg twice a day)
Study: 11583480
Drug: parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib sodium (1 mg, 2 mg, 5 mg, 10 mg, 20 mg, or 40 mg)
Study: 9720702
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of prednisolone in a monthly oral pulse (Group A, aged 12 to 18 years)
Study: 9720702
Drug: Betamethasone sodium
Normalized name: Betamethasone Sodium Phosphate
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone sodium phosphate as soluble tablets or syrup equivalent to prednisolone 5 mg/kg body weight every month (Group B, aged 3 to 11 years)
Study: 9720702
Drug: Pulsed doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed doses of corticosteroid (both groups)
Study: 8131343
Drug: alfacalcidol 0.25
Normalized name: alfacalcidol 0.25 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfacalcidol 0.25 microgram twice daily with calcium 500 mg twice daily
Study: 8131343
Drug: placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily with calcium 500 mg twice daily
Study: 642493
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of albumin during operation followed by 150 g/day for 5 days
Study: 28382336
Drug: Fermented Maillard-reactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Maillard-reactive whey protein (F-MRP) 6 g/day for 8 weeks
Study: 28382336
Drug: Placebo (maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin) 6 g/day for 8 weeks
Study: 21211643
Drug: Timothy grass
Normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy grass allergy immunotherapy tablet (AIT) treatment
Study: 20068276
Drug: Micafungin (MCFG)
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin (MCFG) 2 mg/kg/day (max 100 mg/day)
Study: 20068276
Drug: Fosfluconazole (FF)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfluconazole (FF) 10 mg/kg/day (max 400 mg/day)
Study: 17589370
Drug: Dronabinol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (5 mg)
Study: 26960406
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention with home medication management review
Study: 24595942
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g dehydrated garlic powder
Study: 24595942
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g dehydrated garlic powder
Study: 22265697
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg per day plus goserelin 3.6 mg/month
Study: 22265697
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day plus goserelin 3.6 mg/month
Study: 20147671
Drug: Insulin use
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin use
Study: 14989794
Drug: r‐hFSH and
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hFSH and r‐hLH (150 IU daily)
Study: 14989794
Drug: r‐hFSH and
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hFSH and r‐hLH (150 IU daily) (<35 years)
Study: 14989794
Drug: r‐hFSH and
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hFSH and r‐hLH (150 IU daily) (≥35 years)
Study: 11668407
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of pure cut then blended current
Study: 7905722
Drug: Didanosine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (600 mg/d adjusted for weight)
Study: 7905722
Drug: Zidovudine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (600 mg/d)
Study: 6581281
Drug: Diazepam titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam titration (mean dose = 25.6 mgs)
Study: 6581281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam (12.5 mg), fentanyl (0.1 mg), and methohexital (mean dose = 18.0 mg)
Study: 6581281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam (15.0 mg) and methohexital (mean dose = 27.0 mg)
Study: 31905090
Drug: Tolcapone (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (an inhibitor of catechol‐O‐methyltransferase [COMT])
Study: 31905090
Drug: Bromocriptine (a
Normalized name: Bromocriptine (as bromocriptine mesilate) 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (a DA agonist with preferential affinity for the D2 receptor)
Study: 10697061
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg twice daily
Study: 22039289
Drug: Rimantadine 100
Normalized name: riMANTAdine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine 100 mg twice daily
Study: 22039289
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of oseltamivir and rimantadine
Study: 8821690
Drug: Control (monotherapy)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (monotherapy)
Study: 20054875
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (e.g., olanzapine, quetiapine, risperidone)
Study: 17433007
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (n=26)
Study: 12874615
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/HCTZ 12.5 mg
Study: 11890866
Drug: Immunotherapy (vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (vaccines involving monoclonal antibodies or immune effector cells)
Study: 11890866
Drug: Cell-based therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-based therapies using tumour cells as vaccine components
Study: 11890866
Drug: Immune cells
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune cells (e.g., T-lymphocytes and dendritic cells)
Study: 9928553
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 5 years
Study: 9815522
Drug: Tamoxifen with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen with chemotherapy
Study: 334209
Drug: Diazepam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (7.5 mg and 15 mg)
Study: 334209
Drug: Hydroxyzine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (75 mg and 150 mg)
Study: 25383558
Drug: Multitarget therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitarget therapy (tacrolimus 4 mg/d and mycophenolate mofetil 1.0 g/d)
Study: 25383558
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (0.75 g/m2 every 4 weeks for 6 months)
Study: 23816018
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cTnT with copeptin
Study: 23816018
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hs-cTnT with copeptin
Study: 23816018
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cTnT and copeptin
Study: 23816018
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hs-cTnT and copeptin
Study: 21681372
Drug: Chemoimmunotherapy (NP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (NP chemotherapy followed by vaccination with CEA (605-613) peptide-pulsed autologous dendritic cells and CIK cells, repeated at 30-day intervals for 4 cycles)
Study: 21681372
Drug: Conventional NP
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional NP chemotherapy
Study: 17276750
Drug: Methylphenidate 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.25 mg/kg
Study: 9136493
Drug: Methylphenidate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.5 mg/kg
Study: 17276750
Drug: Methylphenidate 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.125 mg/kg
Study: 15352149
Drug: Long-acting risperidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting risperidone (25, 50, or 75 mg every 2 weeks for up to 50 weeks)
Study: 2968761
Drug: Buserelin (pernasally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (pernasally in conventional doses)
Study: 30839075
Drug: CGAE supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGAE supplementation at 1,000 mg/kg
Study: 23228270
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation size 35.06 to 40.04
Study: 23228270
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation taper from 40.04 to 40.06 in group B
Study: 23228270
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation sizes greater than 40.06
Study: 23228270
Drug: Negative control:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control: preparation size of 25.04
Study: 14698362
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 microg.mL(‐1) at rate of 0.2 mL.kg ‐1.h ‐1 preceded by a bolus of 2 microg.kg ‐1 (CLON group)
Study: 14698362
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 microg.mL ‐1 and ropivacaine 0.1% at rate of 0.2 mL.kg ‐1.h ‐1 (CLON+ROPIV group)
Study: 10652960
Drug: Prednisolone plus
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone plus 15 mg of menatetrenone, three times per day (Group 2)
Study: 8364946
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) 320 mg
Study: 8364946
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) 600 mg
Study: 2439787
Drug: bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (10 mg)